Psoriasis News and Research

Latest Psoriasis News and Research

Intensive exercise answer to psoriasis prevention

Vigorous physical activity may reduce a person’s risk for developing psoriasis, show results from a US study.

30 May 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012.

29 May 2012

EMA CHMP issues positive opinion to Eisai’s Fycompa for treatment of partial-onset seizures

Eisai announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Fycompa (perampanel) as an adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

29 May 2012

Scientists identify new reason why some curry dishes might be good for you

Scientists have just identified a new reason why some curry dishes, made with spices humans have used for thousands of years, might be good for you.

25 May 2012

Children with obesity more likely to have idiopathic intracranial hypertension

Children who are overweight or obese -- particularly older, non-Hispanic white girls -- are more likely to have a neurological disorder known as idiopathic intracranial hypertension, a rare condition that can result in blindness, according to a new Kaiser Permanente study published in The Journal of Pediatrics.

24 May 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012

Data from Almirall, Forest Labs’ aclidinium studies on COPD to be presented at ATS conference

Forest Laboratories, Inc. and Almirall, S.A. today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic Society (ATS) International Conference scheduled May 18 - 23 in San Francisco, CA.

19 May 2012

Studies show vitamin D may benefit cardiovascular, skin and metabolic disorders

The Endocrine Society's new scientific statement published online today represents the first comprehensive evaluation of both the basic and clinical evidence related to the non-skeletal effects of vitamin D. The statement addresses current research regarding the associations of vitamin D with immune function, hypertension, stroke, skin conditions and maternal/fetal health.

19 May 2012

National Psoriasis Foundation awards more than $2 million for research

Twenty-six scientists have received a total of $2.06 million in grants from the National Psoriasis Foundation to study psoriasis—the most common autoimmune disease in the country, affecting as many as 7.5 million Americans—and psoriatic arthritis, an inflammatory joint and tendon disease.

16 May 2012

AAD reiterates safety and effectiveness of sunscreens against UV radiation

The American Academy of Dermatology (Academy) today reiterated the safety and effectiveness of sunscreens to protect against the damaging effects from exposure to ultraviolet (UV) radiation.

16 May 2012

Preclinical evidence demonstrates link between psoriasis and cardiovascular disease

The link between psoriasis and cardiovascular events has been observed for years, however the mechanics were unknown. For the first time, Case Western Reserve University School of Medicine researchers have discovered preclinical evidence demonstrating that the inflammatory skin disease leads to cardiovascular disease. Further, the research demonstrated that aggressive reversal of psoriasis reduces the cardiovascular risk as well.

11 May 2012

Provectus announces final data from PV-10 Phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

9 May 2012

Nuvo receives BfArM positive opinion for Pliaglis

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it has received notice of a positive opinion from the European Decentralized Procedure for the approval of Pliaglis from the German Federal Institute for Drugs and Medical Devices (BfArM), the reference member state.

7 May 2012

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Idera Pharmaceuticals, Inc. today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs).

7 May 2012

Clinical data from Anacor’s tavaborole and AN2728 study to be presented at upcoming meetings

Anacor Pharmaceuticals announced today that it will be presenting clinical data on its lead compounds, tavaborole and AN2728, at the following upcoming medical meetings.

5 May 2012

XenoPort first quarter revenues increase to $10.4 million

XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.

3 May 2012

Idera to present data from IMO-8400 preclinical studies on SLE, psoriasis at AAI meeting

Idera Pharmaceuticals, Inc. today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications.

2 May 2012

Mount Sinai experts to share skin cancer prevention tips on May 7

Skin cancer is the most common form of cancer in the United States, with one in five Americans developing it over the course of their lives. It's also one of the most preventable types of cancers. Since May is Skin Cancer Awareness Month and Melanoma Monday is May 7, Mount Sinai experts are sharing tips on prevention and insight on the new FDA labeling requirements on sunscreen.

30 Apr 2012

InDex Pharmaceuticals granted U.S. patent for novel treatment of steroid-resistant inflammation

InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.

26 Apr 2012

Rare CARD14 gene mutations can lead to plaque psoriasis

Scientists led by Washington University School of Medicine in St. Louis have identified the first gene directly linked to the most common form of psoriasis, a chronic skin condition.

20 Apr 2012

Psoriasis News and Research

Latest Psoriasis News and Research

Intensive exercise answer to psoriasis prevention

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

EMA CHMP issues positive opinion to Eisai’s Fycompa for treatment of partial-onset seizures

Scientists identify new reason why some curry dishes might be good for you

Children with obesity more likely to have idiopathic intracranial hypertension

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Data from Almirall, Forest Labs’ aclidinium studies on COPD to be presented at ATS conference

Studies show vitamin D may benefit cardiovascular, skin and metabolic disorders

National Psoriasis Foundation awards more than $2 million for research

AAD reiterates safety and effectiveness of sunscreens against UV radiation

Preclinical evidence demonstrates link between psoriasis and cardiovascular disease

Provectus announces final data from PV-10 Phase 2 trial on metastatic melanoma

Nuvo receives BfArM positive opinion for Pliaglis

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Clinical data from Anacor’s tavaborole and AN2728 study to be presented at upcoming meetings

XenoPort first quarter revenues increase to $10.4 million

Idera to present data from IMO-8400 preclinical studies on SLE, psoriasis at AAI meeting

Mount Sinai experts to share skin cancer prevention tips on May 7

InDex Pharmaceuticals granted U.S. patent for novel treatment of steroid-resistant inflammation

Rare CARD14 gene mutations can lead to plaque psoriasis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Psoriasis News and Research

Latest Psoriasis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in